Close Menu

NEW YORK – Precision immunology firm Scipher Medicine said on Wednesday that it has entered a collaboration with Galapagos to advance novel drug targets it has identified in analysis of molecular data from patients with inflammatory bowel disease (IBD).

The two companies will jointly validate a set of novel targets that Scipher has discovered using what it calls its Network Medicine Platform, a process that employs artificial intelligence methods and information about protein interaction networks, uncovering potentially druggable pathways and/or therapy-predictive biomarkers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nebula Genomics will be auctioning George Church's genome as a nonfungible token, according to The Scientist.

Anthony Gregg, the outgoing president of the American College of Medical Genetics and Genomics, has resigned after using racially insensitive language. 

Facebook has developed an artificial intelligence approach to predict how drugs interact in cells, New Scientist reports.

In PNAS this week: adaptations among high-altitude Mycobacterium tuberculosis, response of multiple myeloma cells to chemotherapy-induced stress, and more.

Apr
23
Sponsored by
Isoplexis

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

May
10
Sponsored by
MeMed

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

May
20
Sponsored by
ACD

This webinar will present a research project that is using spatial transcriptomics to discern the molecular mechanisms underlying fear memory.